Skip to main content
HealixMedical Supply

Multiplex Respiratory Panel Testing Demand Continues Reshaping Lab and POC Supply Planning

By Healix Editorial Team·May 27, 2026·6 min read

Combined multiplex panels testing for several respiratory pathogens simultaneously continue displacing single-target testing, with real implications for lab and point-of-care supply planning.

Multiplex respiratory panels testing simultaneously for influenza, respiratory syncytial virus, and other common respiratory pathogens in a single specimen have continued displacing older single-target testing approaches, since clinicians and patients alike increasingly prefer the efficiency of a single test yielding a comprehensive result rather than sequential individual pathogen testing.

Why Multiplex Testing Has Won Out

A single multiplex panel provides broader diagnostic information from one specimen collection, reducing both patient discomfort from repeated sampling and the turnaround time delay inherent in sequential single-target testing when an initial negative result prompts a second, different test — a meaningful clinical workflow improvement that has driven strong adoption momentum.

Supply Planning Implications

  • Seasonal demand concentration remains a real planning challenge, since multiplex panel demand still spikes sharply during respiratory illness season even though the panel's broader target coverage somewhat smooths demand relative to needing multiple separate single-target tests
  • Platform-specific cartridge sourcing concentrates supply risk with whichever manufacturer's platform a facility has standardized on, since multiplex cartridges are generally not interchangeable across different testing platforms
  • Cost per test for multiplex panels generally exceeds single-target testing on a per-test basis, requiring facilities to weigh the clinical workflow benefit against the higher unit cost, particularly for lower-acuity patients where a narrower single-target test might be clinically sufficient

Planning for the Coming Season

Labs and point-of-care testing sites with the smoothest seasonal performance place meaningful advance orders ahead of respiratory illness season based on prior-year demand patterns, rather than relying on just-in-time ordering that assumes manufacturers can seamlessly scale supply to match a demand spike in real time.

Facilities managing respiratory testing supply can review Healix Medical Supply's lab supplies catalog.

Medical disclaimer: This article is for general informational purposes only and is not medical advice. Consult a qualified healthcare provider before making decisions about your health or care. Read our editorial policy to learn how this content is researched and reviewed.

Topics:

multiplex respiratory panel testingcombined pathogen test demandrespiratory testing supply planningmultiplex PCR panel adoption 2026seasonal respiratory testing volume

Need Clinical-Grade Medical Supplies?

Healix Medical Supply stocks 400,000+ FDA-cleared products with bulk pricing for healthcare facilities nationwide.